322 related articles for article (PubMed ID: 29493134)
1. [Research advances on astragaloside-IV in treatment of diabetes mellitus and its complications pharmacological effects].
You LZ; Lin YX; Fang ZH; Shen GM; Zhao JD; Wang TT
Zhongguo Zhong Yao Za Zhi; 2017 Dec; 42(24):4700-4706. PubMed ID: 29493134
[TBL] [Abstract][Full Text] [Related]
2. Biological active ingredients of traditional Chinese herb Astragalus membranaceus on treatment of diabetes: a systematic review.
Zhang K; Pugliese M; Pugliese A; Passantino A
Mini Rev Med Chem; 2015; 15(4):315-29. PubMed ID: 25723453
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological effects of Astragaloside IV: a literature review.
Ren S; Zhang H; Mu Y; Sun M; Liu P
J Tradit Chin Med; 2013 Jun; 33(3):413-6. PubMed ID: 24024343
[TBL] [Abstract][Full Text] [Related]
4. Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects.
Zhang J; Wu C; Gao L; Du G; Qin X
Adv Pharmacol; 2020; 87():89-112. PubMed ID: 32089240
[TBL] [Abstract][Full Text] [Related]
5. Research review on the pharmacological effects of astragaloside IV.
Li L; Hou X; Xu R; Liu C; Tu M
Fundam Clin Pharmacol; 2017 Feb; 31(1):17-36. PubMed ID: 27567103
[TBL] [Abstract][Full Text] [Related]
6. The beneficial effects of astragaloside IV on ameliorating diabetic kidney disease.
Gao Y; Su X; Xue T; Zhang N
Biomed Pharmacother; 2023 Jul; 163():114598. PubMed ID: 37150034
[TBL] [Abstract][Full Text] [Related]
7. Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress.
Wang ZS; Xiong F; Xie XH; Chen D; Pan JH; Cheng L
BMC Nephrol; 2015 Mar; 16():44. PubMed ID: 25886386
[TBL] [Abstract][Full Text] [Related]
8. Astragaloside IV acts through multi-scale mechanisms to effectively reduce diabetic nephropathy.
Wang E; Wang L; Ding R; Zhai M; Ge R; Zhou P; Wang T; Fang H; Wang J; Huang J
Pharmacol Res; 2020 Jul; 157():104831. PubMed ID: 32339782
[TBL] [Abstract][Full Text] [Related]
9. Administration of Traditional Chinese Blood Circulation Activating Drugs for Microvascular Complications in Patients with Type 2 Diabetes Mellitus.
He L; Wang H; Gu C; He X; Zhao L; Tong X
J Diabetes Res; 2016; 2016():1081657. PubMed ID: 27830156
[TBL] [Abstract][Full Text] [Related]
10. Astragaloside IV prevents high glucose‑induced cell apoptosis and inflammatory reactions through inhibition of the JNK pathway in human umbilical vein endothelial cells.
You L; Fang Z; Shen G; Wang Q; He Y; Ye S; Wang L; Hu M; Lin Y; Liu M; Jiang A
Mol Med Rep; 2019 Mar; 19(3):1603-1612. PubMed ID: 30628687
[TBL] [Abstract][Full Text] [Related]
11. Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases.
Tan YQ; Chen HW; Li J
Drug Des Devel Ther; 2020; 14():3731-3746. PubMed ID: 32982178
[TBL] [Abstract][Full Text] [Related]
12. Profiling the metabolism of astragaloside IV by ultra performance liquid chromatography coupled with quadrupole/time-of-flight mass spectrometry.
Cheng XD; Wei MG
Molecules; 2014 Nov; 19(11):18881-96. PubMed ID: 25407723
[TBL] [Abstract][Full Text] [Related]
13. Recent pharmacological advances in the treatment of cardiovascular events with Astragaloside IV.
Xu Z; Zhou H; Zhang Y; Cheng Z; Wan M; Qin W; Li P; Feng J; Shao S; Xue W; Guo H; Liu B
Biomed Pharmacother; 2023 Dec; 168():115752. PubMed ID: 37875045
[TBL] [Abstract][Full Text] [Related]
14. Astragaloside IV improves vascular endothelial dysfunction by inhibiting the TLR4/NF-κB signaling pathway.
Leng B; Tang F; Lu M; Zhang Z; Wang H; Zhang Y
Life Sci; 2018 Sep; 209():111-121. PubMed ID: 30081006
[TBL] [Abstract][Full Text] [Related]
15. Astragaloside suppresses tumor necrosis factor receptor-associated factor 5 signaling pathway and alleviates neurodegenerative changes in retinal pigment epithelial cells induced by isoflurane.
Chen PJ; Shang AQ; Wang WW; Yang JP
J Cell Biochem; 2019 Jan; 120(1):1028-1037. PubMed ID: 30277612
[TBL] [Abstract][Full Text] [Related]
16. Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice.
Song G; Han P; Sun H; Shao M; Yu X; Wang W; Wang D; Yi W; Ge N; Li S; Yi T
J Int Med Res; 2018 Jul; 46(7):2883-2897. PubMed ID: 29896981
[TBL] [Abstract][Full Text] [Related]
17. Astragaloside IV inhibits proliferation and promotes apoptosis in rat vascular smooth muscle cells under high glucose concentration in vitro.
Yuan W; Zhang Y; Ge Y; Yan M; Kuang R; Zheng X
Planta Med; 2008 Aug; 74(10):1259-64. PubMed ID: 18622899
[TBL] [Abstract][Full Text] [Related]
18. Effect of astragaloside IV on hepatic glucose-regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin.
Lv L; Wu SY; Wang GF; Zhang JJ; Pang JX; Liu ZQ; Xu W; Wu SG; Rao JJ
Phytother Res; 2010 Feb; 24(2):219-24. PubMed ID: 19610026
[TBL] [Abstract][Full Text] [Related]
19. AMPK in microvascular complications of diabetes and the beneficial effects of AMPK activators from plants.
Shrikanth CB; Nandini CD
Phytomedicine; 2020 Jul; 73():152808. PubMed ID: 30935723
[TBL] [Abstract][Full Text] [Related]
20. Research progress of astragaloside IV in the treatment of atopic diseases.
Yu S; Peng W; Qiu F; Zhang G
Biomed Pharmacother; 2022 Dec; 156():113989. PubMed ID: 36411656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
